GLPwatch

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT06534411 · Active, not recruiting

Last updated 2026-05-28

This study is testing how well the medication CagriSema lowers blood sugar and body weight compared to Tirzepatide in adults with type 2 diabetes who are already taking Metformin, an SGLT2 inhibitor, or both.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 1,023 people
Who can join Ages 18+ · all sexes
Timeline Started 2024-11 · est. completion 2026-07
Where 163 sites · Argentina, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT06534411 ↗

Description as written by the study sponsor.

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Treatments tested

Main thing measuredChange in Glycated Haemoglobin (HbA1c)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06534411 ↗